Personal information

No personal information available

Activities

Collapse all

Employment (1)

Vanderbilt University Medical Center: Nashville, TN, US

1999-05-01 to present | Professor (Medicine)
Employment
Source: Self-asserted source
jordan Berlin

Works (19)

Management of Locally Advanced Rectal Cancer: ASCO Guideline Clinical Insights

JCO Oncology Practice
2025-03 | Journal article
DOI: 10.1200/OP-24-00550
Contributors: Aaron J. Scott; Erin B. Kennedy; Jordan Berlin; Lisa Kachnic; Hagen Kennecke; Sepideh Gholami
Source: check_circle
Crossref

Management of Locally Advanced Rectal Cancer: ASCO Guideline

Journal of Clinical Oncology
2024-10 | Journal article
DOI: 10.1200/JCO.24.01160
Contributors: Aaron J. Scott; Erin B. Kennedy; Jordan Berlin; Gina Brown; Myriam Chalabi; May T. Cho; Mike Cusnir; Jennifer Dorth; Manju George; Lisa A. Kachnic et al.
Source: check_circle
Crossref

A phase I study to evaluate the safety, pharmacokinetics, and pharmacodynamics of PF-06939999 (PRMT5 inhibitor) in patients with selected advanced or metastatic tumors with high incidence of splicing factor gene mutations

ESMO Open
2024-04 | Journal article
DOI: 10.1016/j.esmoop.2024.102961
Contributors: J. Rodon; E. Rodriguez; M.L. Maitland; F.Y.-C. Tsai; M.A. Socinski; J.D. Berlin; J.S. Thomas; T. Al Baghdadi; I.-M. Wang; C. Guo et al.
Source: check_circle
Crossref

Factors and Barriers to Goals-of-Care Conversations for Patients With Cancer and Inpatient Mortality

JCO Oncology Practice
2023-09 | Journal article
DOI: 10.1200/OP.23.00095
Contributors: Margaret Wheless; Julie J. Lee; Henry J. Domenico; Barbara J. Martin; Marc L. Bennett; Sara F. Martin; Jordan Berlin; Jennifer K. Green; Rajiv Agarwal
Source: check_circle
Crossref

Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours – A systematic review and meta-analysis

European Journal of Cancer
2023-03 | Journal article
DOI: 10.1016/j.ejca.2022.12.031
Contributors: Satya Das; Sharon Phillips; Cody L. Lee; Rajiv Agarwal; Emily Bergsland; Jonathan Strosberg; Jennifer A. Chan; Heather LaFerriere; Robert A. Ramirez; Jordan Berlin et al.
Source: check_circle
Crossref

Appendix from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22483598
Contributors: E. Gabriela Chiorean; Katherine A. Guthrie; Philip A. Philip; Elizabeth M. Swisher; Florencia Jalikis; Michael J. Pishvaian; Jordan Berlin; Marcus S. Noel; Jennifer M. Suga; Ignacio Garrido-Laguna et al.
Source: check_circle
Crossref

Appendix from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22483598.v1
Contributors: E. Gabriela Chiorean; Katherine A. Guthrie; Philip A. Philip; Elizabeth M. Swisher; Florencia Jalikis; Michael J. Pishvaian; Jordan Berlin; Marcus S. Noel; Jennifer M. Suga; Ignacio Garrido-Laguna et al.
Source: check_circle
Crossref

Data from Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6529815
Contributors: Anna M. Varghese; Dana B. Cardin; Jonathan Hersch; Al B. Benson; Howard S. Hochster; Lukas Makris; Kensuke Hamada; Jordan D. Berlin; Leonard B. Saltz
Source: check_circle
Crossref

Data from Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6529815.v1
Contributors: Anna M. Varghese; Dana B. Cardin; Jonathan Hersch; Al B. Benson; Howard S. Hochster; Lukas Makris; Kensuke Hamada; Jordan D. Berlin; Leonard B. Saltz
Source: check_circle
Crossref

Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6531176
Contributors: E. Gabriela Chiorean; Katherine A. Guthrie; Philip A. Philip; Elizabeth M. Swisher; Florencia Jalikis; Michael J. Pishvaian; Jordan Berlin; Marcus S. Noel; Jennifer M. Suga; Ignacio Garrido-Laguna et al.
Source: check_circle
Crossref

Data from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.c.6531176.v1
Contributors: E. Gabriela Chiorean; Katherine A. Guthrie; Philip A. Philip; Elizabeth M. Swisher; Florencia Jalikis; Michael J. Pishvaian; Jordan Berlin; Marcus S. Noel; Jennifer M. Suga; Ignacio Garrido-Laguna et al.
Source: check_circle
Crossref

Supplementary Data from Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22478013
Contributors: Anna M. Varghese; Dana B. Cardin; Jonathan Hersch; Al B. Benson; Howard S. Hochster; Lukas Makris; Kensuke Hamada; Jordan D. Berlin; Leonard B. Saltz
Source: check_circle
Crossref

Supplementary Data from Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22478013.v1
Contributors: Anna M. Varghese; Dana B. Cardin; Jonathan Hersch; Al B. Benson; Howard S. Hochster; Lukas Makris; Kensuke Hamada; Jordan D. Berlin; Leonard B. Saltz
Source: check_circle
Crossref

Table S1 and Table S2 from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22483595
Contributors: E. Gabriela Chiorean; Katherine A. Guthrie; Philip A. Philip; Elizabeth M. Swisher; Florencia Jalikis; Michael J. Pishvaian; Jordan Berlin; Marcus S. Noel; Jennifer M. Suga; Ignacio Garrido-Laguna et al.
Source: check_circle
Crossref

Table S1 and Table S2 from Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

2023-03-31 | Preprint
DOI: 10.1158/1078-0432.22483595.v1
Contributors: E. Gabriela Chiorean; Katherine A. Guthrie; Philip A. Philip; Elizabeth M. Swisher; Florencia Jalikis; Michael J. Pishvaian; Jordan Berlin; Marcus S. Noel; Jennifer M. Suga; Ignacio Garrido-Laguna et al.
Source: check_circle
Crossref

First-in-human trial exploring safety, antitumor activity, and pharmacokinetics of Sym013, a recombinant pan-HER antibody mixture, in advanced epithelial malignancies

Investigational New Drugs
2022-06 | Journal article
DOI: 10.1007/s10637-022-01217-7
Contributors: Jordan Berlin; Anthony W. Tolcher; Cliff Ding; Jennifer G. Whisenant; Ivan D. Horak; Debra L. Wood; Paul I. Nadler; Ulla Holm Hansen; Johan Lantto; Niels Jørgen Ø. Skartved et al.
Source: check_circle
Crossref

Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update

Journal of Clinical Oncology
2022-03-10 | Journal article
DOI: 10.1200/JCO.21.02538
Contributors: Nancy N. Baxter; Erin B. Kennedy; Emily Bergsland; Jordan Berlin; Thomas J. George; Sharlene Gill; Philip J. Gold; Alex Hantel; Lee Jones; Christopher Lieu et al.
Source: check_circle
Crossref

Randomized Phase II Study of PARP Inhibitor ABT-888 (Veliparib) with Modified FOLFIRI versus FOLFIRI as Second-line Treatment of Metastatic Pancreatic Cancer: SWOG S1513

Clinical Cancer Research
2021-12-01 | Journal article
DOI: 10.1158/1078-0432.CCR-21-1789
Contributors: E. Gabriela Chiorean; Katherine A. Guthrie; Philip A. Philip; Elizabeth M. Swisher; Florencia Jalikis; Michael J. Pishvaian; Jordan Berlin; Marcus S. Noel; Jennifer M. Suga; Ignacio Garrido-Laguna et al.
Source: check_circle
Crossref

Phase I Study of Trifluridine/Tipiracil Plus Irinotecan and Bevacizumab in Advanced Gastrointestinal Tumors

Clinical Cancer Research
2020-04-01 | Journal article
DOI: 10.1158/1078-0432.CCR-19-2743
Contributors: Anna M. Varghese; Dana B. Cardin; Jonathan Hersch; Al B. Benson; Howard S. Hochster; Lukas Makris; Kensuke Hamada; Jordan D. Berlin; Leonard B. Saltz
Source: check_circle
Crossref

Peer review (5 reviews for 4 publications/grants)

Review activity for Cancer chemotherapy and pharmacology. (1)
Review activity for Clinical colorectal cancer. (1)
Review activity for JNCI cancer spectrum. (1)
Review activity for Journal of the National Cancer Institute : (2)
How many people are using ORCID?